Offer - Urjas Oil for just ₹ 1
Brimofinet is a prescription drug, available for use as Drops. Secondary and off-label uses of Brimofinet have also been mentioned below.
The optimal dosage of Brimofinet is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
The most common side effects of Brimofinet are Eye Burning, Eye irritation, Stinging in the Eyes. Apart from the aforementioned side effects, Brimofinet can also lead to other problems, which have been listed below. Usually, these side effects of Brimofinet go away soon, and do not persist beyond the duration of the treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
In addition, Brimofinet's effect is Mild during pregnancy and Unknown for lactating mothers. In addition, Brimofinet's effects on the liver, heart and kidney are discussed below in the Brimofinet related warnings section.
Brimofinet is not recommended if you suffer from certain medical conditions as it can have adverse effects. Heart Failure, Diabetes, COPD (Chronic Obstructive Pulmonary Disease) are examples of such conditions. Some other conditions that can be affected by Brimofinet are listed in the contraindications section below.
Besides this, Brimofinet may also have severe interaction with some medicines. See below for a complete list.
In addition to these precautions, you may also note that Brimofinet is safe while driving, and is is addictive in nature.
Brimofinet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
| Adult |
|
| Geriatric |
|
Is the use of Brimofinet safe for pregnant women?
Pregnant women may get mild side effects from Brimofinet.
Is the use of Brimofinet safe during breastfeeding?
No research work has been carried out till date on effect of Brimofinet on breastfeeding women. So it is not known whether taking Brimofinet will cause side effects or not.
What is the effect of Brimofinet on the Kidneys?
There may be some adverse effects on kidney after taking Brimofinet. If you observe any such side effects, stop taking this drug. Consume this medicine again only if your doctor advises you to do so.
What is the effect of Brimofinet on the Liver?
The liver can be affected by Brimofinet. If you experience any unwanted effects of this drug, stop taking it and consult your doctor. You should restart Brimofinet only after medical advice.
What is the effect of Brimofinet on the Heart?
You may experience side effects on your heart after taking Brimofinet. If this happens, then discontinue its use. Consult your medical practitioner, and do as he/she suggests.
Brimofinet should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Brimofinet unless your doctor advises you to do so -
Is this Brimofinet habit forming or addictive?
No, you will not get addicted to Brimofinet.
Interaction between Food and Brimofinet
Taking Brimofinet with food does not harm your health.
Interaction between Alcohol and Brimofinet
Information about the interaction of Brimofinet and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Istalol® (timolol maleate ophthalmic solution)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1401
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 153
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1405
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 154
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Alphagan® (brimonidine tartrate)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Simbrinza™ (brinzolamide/brimonidine tartrate)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Enidin® (brimonidine tartrate)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Alphagan® P (brimonidine tartrate)
